Related Experiment Videos
Effect of alpha- and beta-blocker therapy on blood lipids: European experience
Insights
Certain blood pressure medications can negatively impact blood lipid levels. Beta-blockers like propranolol may lower high-density lipoprotein cholesterol and increase triglycerides, while prazosin shows a more favorable lipid profile.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Research
Background:
- Hypertension is a known coronary risk factor, but drug trials haven't definitively proven prevention of heart disease.
- Concerns exist regarding adverse metabolic effects of antihypertensive drugs, particularly on blood lipids.
Purpose of the Study:
- To investigate the specific effects of various antihypertensive drugs on blood lipid profiles.
- To evaluate the impact of different drug classes on cholesterol and triglyceride levels.
Main Methods:
- Analysis of data from the Oslo Study on mild hypertension treatment.
- Design of specific trials to assess antihypertensive drugs' effects on lipids.
- Review of European studies on antihypertensive treatment and lipid metabolism.
Main Results:
- Propranolol significantly decreased high-density lipoprotein cholesterol and increased triglycerides.
- Prazosin reduced total cholesterol, LDL+VLDL cholesterol, and triglycerides.
- Pindolol showed minimal impact on lipid levels, while other beta-blockers like oxprenolol and atenolol affected lipids similarly to propranolol.
Conclusions:
- Some antihypertensive drugs, particularly beta-blockers, can adversely affect blood lipid profiles.
- Prazosin demonstrates a more favorable effect on lipids compared to certain beta-blockers.
- Further research is needed to understand the clinical implications of these lipid changes in hypertension management.
Abstract:
Although hypertension is a well-established coronary risk factor, controlled, randomized hypertension drug trials have failed to show a definite preventive effect on the incidence of coronary heart disease. Possible adverse metabolic effects, particularly on blood lipids, of some commonly used antihypertensive drugs have been investigated. During the Oslo Study on the treatment of mild hypertension, which was not specifically designed to study the effect on lipids, a decrease in serum high-density lipoprotein cholesterol and an increase in serum triglycerides was observed with a combination of propranolol and hydrochlorothiazide. Therefore, special trials were designed specifically to study the effect of various antihypertensive drugs on blood lipids. Propranolol reduced serum high-density lipoprotein cholesterol (13 percent) and the cholesterol ratio [high-density lipoprotein cholesterol:(low-density lipoprotein cholesterol plus very low-density lipoprotein cholesterol)] by 15 percent and increased total serum triglycerides by 24 percent. Prazosin significantly (p less than 0.01) reduced total serum cholesterol, (9 percent) low-density lipoprotein cholesterol plus very low-density lipoprotein cholesterol (10 percent), and total triglycerides (16 percent), whereas the cholesterol ratio increased by 7 percent. The reduction in high-density lipoprotein cholesterol with propranolol plus prazosin was less than that with propranolol alone. Pindolol (with a high sympathomimetic activity) did not significantly change total cholesterol, low-density lipoprotein cholesterol plus very low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, or total triglycerides. Prazosin plus pindolol reduced serum low-density lipoprotein cholesterol plus very low-density lipoprotein cholesterol. The observed reductions in serum high-density lipoprotein cholesterol and the cholesterol ratio with oxprenolol were 11.5 percent and 13.7 percent, respectively, and with atenolol 16.7 percent and 19.2 percent, respectively, whereas total serum triglycerides were increased by 14.9 percent with oxprenolol and 17.9 percent with atenolol. Data provided by other European groups comparing the effect of antihypertensive treatment on lipid metabolism are also reviewed.